Concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in painful bone metastasis of breast cancer origin

Ahmed, Shaimaa; Kamal, Sherif; Salah, Tarek; Sedik, Mayada Fawzy; Youssief, Ayatallah A.

doi:10.1016/j.jbo.2021.100395

Cited by 6 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1); these studies, published between 2002 and 2021, involved a total of 860 patients. [9][10][11][12][13][14][15][16][17][18][19] Eight of the included studies originated from lower-middle-income countries, 10,[12][13][14][15][17][18][19] while the remaining studies were conducted in upper-middleincome countries. 9,11,16 Specifically, eight studies were conducted in various countries in Asia (Turkey, Iran, India, Malaysia), [9][10][11][12][13][15][16][17] and the remaining studies were conducted in a country in Africa (Egypt).…”

Section: Search Resultsmentioning

confidence: 99%

“…9,11,16 Specifically, eight studies were conducted in various countries in Asia (Turkey, Iran, India, Malaysia), [9][10][11][12][13][15][16][17] and the remaining studies were conducted in a country in Africa (Egypt). 14,18,19 Study designs included six prospective randomized studies, 10,12,14,15,18,19 four prospective non-randomized studies, 9,11,13,17 and one retrospective study. 16 The main characteristics and outcomes of the selected studies are summarized in Table 1.…”

Section: Search Resultsmentioning

confidence: 99%

“…The authors reported only mild toxicities, without statistically significant differences between the two groups. 19…”

Section: Search Resultsmentioning

confidence: 99%

“…2). [9][10][11][12][13][14][15][16][17][18][19] IIn the selected trials from HIC, [22][23][24][25][26][27][28][29][30][31][32][33][34][35] CR rates in single fraction RT ranged from 0% to 61.5% (median: 23.8%), while in multiple fractions RT, the rates ranged from 8.8% to 50.8% (median: 27.6%). 20 Furthermore, the PR rates ranged from 11.4% to 76% (median: 35.6%) for single fraction RT and from 14.2% to 88% (median: 37.8%) for multiple fractions RT (Table 3, Fig.…”

Section: Pain Reliefmentioning

confidence: 99%

See 3 more Smart Citations

Assessing the effectiveness of palliative radiotherapy for painful bone metastases in low‐ and middle‐income countries: A systematic review

Kaganda Bomboka,

Galietta,

Donati

et al. 2024

J Med Imag Rad Onc

View full text Add to dashboard Cite

Palliative radiotherapy (RT) effectively relieves pain in patients with bone metastases (BMs). Furthermore, several clinical trials, in most cases conducted in high‐income countries (HICs), proved that single‐fraction RT is equally effective compared to multi‐fractionated RT. However, the evidence is scarce regarding low/middle‐income countries (LMICs), where the diagnosis of BMs could be later and RT techniques less advanced. Therefore, we conducted a systematic literature review to evaluate the efficacy of palliative RT of BMs in the LMIC setting. A literature search was performed independently by two authors on the PubMed, Cochrane and Scopus databases. Overall, 333 records were screened and after the selection process, 11 papers were included in the analysis. Complete pain response rates ranged from 11.5% to 37.1% (median: 22%) for single‐fraction RT and from 0% to 35.1% (median: 19%) for multi‐fractionated RT. Partial pain response rates ranged from 23.1% to 76.9% (median: 53.8%) for single fraction RT and from 23.8% to 84.6% (median: 65%) for multi‐fractionated RT. Four randomized trials compared single‐fraction RT with multiple‐fraction RT and none of them showed significant differences in terms of pain relief. Our analysis showed that pain response rates after palliative RT recorded in LMIC are like those reported in studies performed in HIC. Even in this setting, RT in single fraction shows comparable pain response rates to multifractional RT.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Search Resultsmentioning

confidence: 99%

“…The authors reported only mild toxicities, without statistically significant differences between the two groups. 19…”

Section: Search Resultsmentioning

confidence: 99%

Section: Pain Reliefmentioning

confidence: 99%

See 2 more Smart Citations

Assessing the effectiveness of palliative radiotherapy for painful bone metastases in low‐ and middle‐income countries: A systematic review

Kaganda Bomboka,

Galietta,

Donati

et al. 2024

J Med Imag Rad Onc

View full text Add to dashboard Cite

show abstract

“…Concurrent chemoradiotherapy for painful bone metastases from breast cancer is tolerable and effective. In a prospective study including 84 patients with painful bone metastases from breast cancer, who were randomized to receive a dose of 30 Gy in 10 fractions with or without 825 mg/m 2 capecitabine every 12 h, the complete response rate to pain at week 4 was 42.9% with capecitabine and 19% without capecitabine, with similar therapeutic toxicity noted in both groups [ 193 ].…”

Section: Therapies For Bone Metastasismentioning

confidence: 99%

Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

Pang

Gan

et al. 2022

Cancers

View full text Add to dashboard Cite

Bone metastasis is a common complication of many types of advanced cancer, including breast cancer. Bone metastasis may cause severe pain, fractures, and hypercalcemia, rendering clinical management challenging and substantially reducing the quality of life and overall survival (OS) time of breast cancer patients. Studies have revealed that bone metastasis is related to interactions between tumor cells and the bone microenvironment, and involves complex molecular biological mechanisms, including colonization, osteolytic destruction, and an immunosuppressive bone microenvironment. Agents inhibiting bone metastasis (such as bisphosphate and denosumab) alleviate bone destruction and improve the quality of life of breast cancer patients with bone metastasis. However, the prognosis of these patients remains poor, and the specific biological mechanism of bone metastasis is incompletely understood. Additional basic and clinical studies are urgently needed, to further explore the mechanism of bone metastasis and develop new therapeutic drugs. This review presents a summary of the molecular mechanisms and therapeutic strategies of bone metastasis of breast cancer, aiming to improve the quality of life and prognosis of breast cancer patients and provide a reference for future research directions.

show abstract

The integration of radiotherapy with systemic therapy in advanced triple-negative breast cancer

Yang

2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in painful bone metastasis of breast cancer origin

Abstract: Graphical abstract

Cited by 6 publications

References 26 publications

Assessing the effectiveness of palliative radiotherapy for painful bone metastases in low‐ and middle‐income countries: A systematic review

Assessing the effectiveness of palliative radiotherapy for painful bone metastases in low‐ and middle‐income countries: A systematic review

Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies

The integration of radiotherapy with systemic therapy in advanced triple-negative breast cancer

Contact Info

Product

Resources

About